Financing channel feed – Endpoints News

Financing channel feed

A new AI startup has emerged, and Pfizer likes what it sees

4 years ago

Maze Therapeutics refuels with another $190M to prove its genetic modifiers approach holds up in the clinic

4 years ago

A new startup thinks it's found a key to drugging 'disordered' proteins — and it has plenty of cash to get started

4 years ago

Anacor veterans raise $80M in bid to tackle rare lung disease with boron-based inhibitors

4 years ago

ALS player Amylyx bags $190M as it sets sail on Nasdaq amid choppy waters

4 years ago

Foresite's immunology play gets a $200M megaround for TYK2 program, rebranding as Alumis

4 years ago

Biosimulation outfit nets $15M Series A in push to make preclinical R&D more predictable

4 years ago

Gene therapy player Affinia aims to go public, hoping to raise big money in effort to remake AAVs

4 years ago

Can RNA editing take Atlas startup where Vertex couldn't go? Korro lands $116M to find out

4 years ago

Gene therapy 3.0 efforts net SalioGen a nine-figure Series B, but much remains under wraps

4 years ago

Taking notes from MD Anderson and Rice University, Avenge Bio uncloaks with $45M and a slate of immunotherapies

4 years ago

European biotech VC closes first fund with over $120M in the bank, thanks to big investors

4 years ago

Low-profile RNAi player lands on HKEX following modest $50M IPO

4 years ago

A Jeff Aronin startup quietly yanks its IPO as the biotech market ends year on a whimper

4 years ago

Innogen nets $120M to advance Trulicity, Ozempic rival; venture into manufacturing

4 years ago

Biotech vets jump on board a startup, raise cash and take aim at the clinic with anti-inflammatory drugs

4 years ago

Third Rock's Ambys closes a megaround with the clinic still a ways off for its regenerative cells for liver disease

4 years ago

Weeks after $143M megaround, low-profile CinCor looks to vault onto Nasdaq with a Roche castoff

4 years ago

Biotech startup lines up more cash to steer its NASH drug through stormy seas

4 years ago

Omega Funds goes back to the well with newest $650M fund, taking a 'stage-agnostic' approach to biotech VC

4 years ago

Amylyx takes its ALS program to Nasdaq, raising the stakes for the biotech's only drug

4 years ago

After 7 years in stealth, UC Berkeley spinout Nodexus emerges with an RA Capital-backed Series A

4 years ago

The next-gen IL-2 race heats up as Anaveon secures a megaround with its sights set on mid-stage tests

4 years ago

Italian cancer gene therapy biotech makes history with modest Nasdaq IPO

4 years ago

First page Previous page 60 61 626364 65 66 Next page Last page